Biogen Inc

Baxalta’s (BXLT) product portfolio can be divided into three parts: hematology, immunology, and oncology.

Wall Street analysts have projected that Teva Pharmaceutical Industries (TEVA) will earn about $3.5 billion in revenues from Copaxone sales in 2016

AbbVie (ABBV) has continued to improve its operational efficiency, which is expected to result in a net profit margin of 29.8%, a YoY increase of 6.3%. In 3Q15, AbbVie realized a net proft margin of 30.4%.

In 3Q15, Celgene had a strong inflammation and immunology pipeline. The company witnessed the progress of its key investigational drug GED-0301.

In 3Q15, Biogen saw several positive developments for the drugs developed under its various collaborative arrangements.

Novo Nordisk is pursuing leadership in the hemophilia market with its new drugs as well as a few investigational hemophilia drugs in its late-stage research pipeline.

AbbVie’s business model involves generating revenues through the sale of pharmaceutical products, which target some of the world’s most serious diseases.

Enhancing its manufacturing capability, Amgen has launched a next-generation bio-manufacturing facility in Singapore and plans to set up more in the coming years.

Amgen (AMGN) has adopted a well-structured research and development strategy focused on inflammation, metabolism, bone, and cardiovascular diseases.

With a market capitalization of $50.7 billion, Regeneron is one of the country’s major biotechnology companies. Its products and pipeline candidates focus on cancer, eye diseases, and cardiovascular diseases.

Celgene’s EBITDA margins were lower than those of its competitors. Its R&D investment appears to be higher than its peers, and its SG&A expenses have risen.

Celgene has consistently delivered breakthrough innovations in biotechnology and has as actively pursued acquisitions of companies for access to compounds.

The strong leadership of Gilead’s talented scientists has enabled the company to consistently deliver innovative therapies in the market.

In 2Q15, Biogen (BIIB) posted mixed results for its pipeline drugs. Investor sentiment remained favorable for its innovative multiple sclerosis (or MS) drugs.

If approved, solanezumab would be a breakthrough therapy in the Alzheimer’s market. The drug actually seeks to cure the cognitive disease, not simply treat it.

In 2014, Biogen earned about 27% of its total revenues from international markets such as Canada, Europe, and emerging economies.

One of the world’s leading biotechnology companies, Biogen specializes in manufacturing and marketing therapies to treat serious ailments related to the nervous system, immune system, and blood.

A leader in the development of multiple sclerosis treatments, Biogen earned 82.5% of its total revenues from its MS drugs in 2014.

When a US biotechnology company uses market entry strategies to launch its drug directly in the European market, it has to bear all the expenses related to the drug approval process in Europe.

Most multiple sclerosis drugs are very costly at about $55,000 per year. The FDA’s April 2015 approval of a generic version of Copaxone is expected to lower the overall price of the therapy.

After 2012, the biotechnology industry (IBB) had a period of solid growth, mainly driven by novel scientific inventions and aggressive commercial distribution.

A drug approval process is required in order for a new drug to enter the market. Companies with new drugs in later stages of the approval process are more likely to earn a positive cash flow in the next few years.

The aging Baby Boomer population in the United States is one of the social factors driving the US healthcare industry. By 2030, Americans over 55 will be 31% of the population.

Compared to pure-play pharmaceutical companies, the biotechnology industry is more sensitive to economic factors such as changes in GDP, interest rates, and exchange rates.

The type of business model a biotechnology company selects depends on technical capability, availability of resources, and competition in the industry.

The two main classifications for drugs are chemical compound drugs and biologics. Medicinal drugs are broadly classified as prescription drugs and over-the-counter drugs.

Biotechnology is simply ‘technology based on biology.’ The biotechnology industry includes food technology, genetic research, healthcare, and environmental technology.

As the US economy expands, innovation seems to be the tide that is lifting all boats. Innovation is being driven by technology.